Objective To assess the effect of interstitial implant with sustained- release 5-fluorouracill during radical pancreatectomy in pancreatic cancer. Methods The clinicopathological data were collected from 106 patients who had received surgical operation from January 2008 to January 2011. The ciinicopathalogical features were retrospectively analyzed and were divided into 2 groups: treatment group (n -49), patients with intraoperative implant sustained-release 5-fluorouracill; control group (n =57), patients without intraperitoneal chemotherapy. The clinical benefit response (CBR) and survival of patients of the two groups were observed. Results In treatment group CBR rate was 65.3% and 45.6% for the control group ( P <0. 05). Median survival time was 20 vs 13 months for the treatment and control group respectively (P <0.05). Disease -free survival (DFS) rate was 65.4% of 1 year in treatment group, and in control group DFS rate was 39.1% of 1 year (P<0.01). Overall survival (OS) rate was 71.3% of 1 year in treatment group, and in control group OS rate was 55.9% of 1 year (P<0.05). Conclusion Intraperitoneal interstitial implant with sustained-release 5-fluorouracill is an effective measure to prevent local recurrence, improve the quality of life and prolong the survival rate in resected pancreatic cancer.%目的 评价胰腺癌根治术中腹腔内植入5-氟尿嘧啶缓释剂的疗效.方法 收集2008年1月-2011年1月106例行根治性切除术的胰腺癌患者的临床病理学资料,分析其临床病理学特征并分组,49例术中植入5-氟尿嘧啶缓释剂作为治疗组,57例未进行术中化疗作为对照组.观察两组临床受益反应及生存情况.结果 治疗组与对照组临床受益率分别为65.3％和45.6％(P＜0.05)；中位生存时间分别为20和13个月(P＜0.05)；1年无病生存率分别为65.4％和39.1％(P＜0.01)；1年总生存率分别为71.3％和55.9％ (P ＜0.05).结论 术中即时植入5-氟尿嘧啶缓释剂可降低胰腺癌患者术后肿瘤的复发,提高患者生活质量,明显延长生存时间.
展开▼
